Heron therapeutics, inc. HRTX.US Overview
HRTX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
HRTX Current Performance
-3.77%
Heron therapeutics, inc.
-1.83%
Avg of Sector
-0.40%
S&P500
HRTX Key Information
HRTX Revenue by Segments
Browsing restrictions can be lifted for a fee.
HRTX Net Income
Browsing restrictions can be lifted for a fee.
HRTX Cash Flow
Browsing restrictions can be lifted for a fee.
HRTX Profit Margin
Browsing restrictions can be lifted for a fee.
HRTX PE Ratio River
Browsing restrictions can be lifted for a fee.
HRTX Financial Forecast
Browsing restrictions can be lifted for a fee.
HRTX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
HRTX Profile
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Price of HRTX
HRTX FAQ
When is HRTX's latest earnings report released?
The most recent financial report for Heron therapeutics, inc. (HRTX) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HRTX's short-term business performance and financial health. For the latest updates on HRTX's earnings releases, visit this page regularly.
What is the operating profit of HRTX?
According to the latest financial report, Heron therapeutics, inc. (HRTX) reported an Operating Profit of 3.15M with an Operating Margin of 8.11% this period, representing a growth of 165.74% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is HRTX's revenue growth?
In the latest financial report, Heron therapeutics, inc. (HRTX) announced revenue of 38.9M, with a Year-Over-Year growth rate of 12.21%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does HRTX have?
As of the end of the reporting period, Heron therapeutics, inc. (HRTX) had total debt of 177.26M, with a debt ratio of 0.75. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does HRTX have?
At the end of the period, Heron therapeutics, inc. (HRTX) held Total Cash and Cash Equivalents of 19.27M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does HRTX go with three margins increasing?
In the latest report, Heron therapeutics, inc. (HRTX) achieved the “three margins increasing” benchmark, with a gross margin of 78.3%%, operating margin of 8.11%%, and net margin of 6.8%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess HRTX's profit trajectory and future growth potential.
Is HRTX's EPS continuing to grow?
According to the past four quarterly reports, Heron therapeutics, inc. (HRTX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.02. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of HRTX?
Heron therapeutics, inc. (HRTX)'s Free Cash Flow (FCF) for the period is -8.94M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.08% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of HRTX?
The latest valuation data shows Heron therapeutics, inc. (HRTX) has a Price-To-Earnings (PE) ratio of -47.43 and a Price/Earnings-To-Growth (PEG) ratio of -1.96. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.